Trials / Completed
CompletedNCT00891709
LEO 29102 Single and Multiple Dose Study by Dermal Application
A Phase 1, First in Man, Safety, Tolerability and Pharmacokinetic Study of Single Ascending and Multiple Cutaneous Doses of LEO 29102 2.5 mg/g Cream or LEO 29102 Cream Vehicle in Healthy Male Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 64 (actual)
- Sponsor
- LEO Pharma · Industry
- Sex
- Male
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The principal aim of this study is to obtain safety, tolerability and pharmacokinetic data when LEO 29102 is administered cutaneously as single and multiple doses to healthy male subjects. The study is divided into one single dose part followed by a multiple dose part.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LEO 29102 | First-in-man. Healthy volunteers |
Timeline
- Start date
- 2009-03-01
- Primary completion
- 2009-06-01
- Completion
- 2009-06-01
- First posted
- 2009-05-01
- Last updated
- 2025-02-24
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT00891709. Inclusion in this directory is not an endorsement.